Navigation Links
Tianyin Pharmaceutical Appoints Three New Independent Board Members
Date:3/4/2008

Additions Bring Experience and Expertise in the Chinese Pharmaceutical

Industry, International Business Operations and Finance

CHENGDU, China, March 4 /Xinhua-PRNewswire-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc., (OTC Bulletin Board: VSCO), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced three new independent board members: Professor Zunjian Zhang, Ph.D., Professor Jianping Hou, Ph.D. and Mr. James T. McCubbin, who will serve along with Dr. Guoqing Jiang and Mr. Stewart Shiang Lor.

Dr. Guoqing Jiang, MD, the CEO, will serve as Chairman of the Board. He led the group that purchased Tianyin Pharmaceutical in 2003 which, under his leadership, has become a leading traditional Chinese medicine manufacturer and supplier in China. Prior to this, Dr. Jiang served as CEO at Kelun Pharmaceutical Group from December 1996 to July 2003, where he built the company from inception to become one of the leading producers of intravenous solution products and distributor of traditional Chinese medicine products and pharmaceuticals. Currently, Kelun is the world's largest producer of intravenous solution products and one of China's leading distributors of pharmaceutical and traditional Chinese medicine products with revenues in excess of US$700 million annually and has over 7,000 employees.

Mr. Lor leverages over 20 years of experience in diverse disciplines, including corporate management, manufacturing and operations, international trade, corporate finance and investment, financial consulting, information technology as well as sales and marketing. He co-founded Lorons International Corporation, Powerbridge Technology Co., Ltd. and Cmark Capital Co., Ltd. and served in various senior management positions at several international and China based companies.

Professor Zunjian Zhang, Ph.D. is currently a graduate school faculty advisor at China Pharmaceutical Universi
'/>"/>

SOURCE Tianyin Pharmaceutical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results
2. Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST
3. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
4. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
5. SGX Pharmaceuticals Schedules Teleconference and Webcast for Fourth Quarter and Full Year 2007 Results
6. NPS Pharmaceuticals to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
7. NuRx Pharmaceuticals Retains Russo Partners for Investor Relations, Corporate Communications Counsel
8. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
9. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
10. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
11. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 On Friday, December 19, ... the Omnibus and Continuing Resolution Appropriations Act of ... a condition eligible to receive funding through the ... the Department of Defense (DoD). The Hydrocephalus Association ... Capitol Hill, is celebrating this victory for the ...
(Date:12/24/2014)... San Diego, CA (PRWEB) December 23, 2014 ... Contest where their Twitter followers can submit their ... for themselves and their lab mates. , For those ... beloved lab mates, the Pipette.com Holiday in the Lab ... encourages Pipette.com Twitter followers to send pictures ...
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., ... has filed a Clinical Trial Application (CTA) with the ... Regulatory Agency (MHRA) seeking regulatory approval to initiate clinical ... Anatabine Citrate. Contingent on the Company receiving ... Phase I trial to assess the safety, tolerability and ...
(Date:12/22/2014)... N.C. , Dec. 22, 2014  Alternative ... announced that it has signed a letter of ... that has developed and patented a nanotechnology-based development ... diagnostics products that enable rapid on-site collection and ... use/abuse and health issues in an immediate, non-invasive ...
Breaking Biology Technology:Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3ALNE Announces Intention To Acquire BioTechPharma 2
... , PRINCETON, N.J., Aug. 4 DOR ... Company), a late-stage biopharmaceutical company, announced today that the ... Food and Drug Administration (FDA) has granted Orphan Drug ... the treatment of gastrointestinal symptoms associated with chronic Graft-versus-Host ...
... , FT. LAUDERDALE, Fla., Aug. 4 OmniComm ... electronic data capture (EDC) solutions for clinical trials announced today ... based, clinical software provider, Logos Technologies, Ltd. The acquisition will ... , , Logos, exceptional software is used ...
... , BEIJING, Aug. 4 /PRNewswire-Asia/ -- ... provider of vaccines in China, announced today,that the clinical trial ... volunteers received their first shot of the vaccine and, during ... A/H1N1,influenza vaccine is safe and reliable in humans. , ...
Cached Biology Technology:DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD 2DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD 3DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD 4DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD 5DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD 6OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor - Logos Technologies, Ltd. 2OmniComm Systems Acquires EDC Assets of Leading Phase I Clinical Software Vendor - Logos Technologies, Ltd. 3Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials 2Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials 3
(Date:12/11/2014)... Dec. 10, 2014  Data Sciences International (DSI), ... released a new series of digital telemetry implants ... researchers. M series, part of the PhysioTel™ Digital ... best possible physiologic data when incorporating functional endpoints ... endpoints to toxicology studies has evolved from short ...
(Date:12/10/2014)... RALEIGH, N.C. , Dec. 9, 2014  Valencell, ... announced it is seeing a staggering demand from its ... demand, the Company revealed, is not solely coming from ... industries as well. "A wearable is only ... a result, accuracy is the ultimate driver in long-term ...
(Date:12/10/2014)... 2014 CIE San Diego has launched an ... connective tissue that enhances care coordination among social service ... client-level information; earned a second $1 million grant from ... seniors aging in community and; will be recognized as ... th 4-6p. CIE San Diego today ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... of bacteria may be genetically identical, individual bacteria within that ... is crucial in the bacteria,s struggle for survival. The more ... will contain individuals able to take advantage of a new ... by an antibiotic. In a recent study, researchers at ...
... organ in your body that can sense cigarette smoke wafting through ... University of Iowa have showed that your lungs have odor receptors ... located in the membranes of nerve cells, the ones in your ... nerve impulses to your brain that allow it to "perceive" the ...
... pain reliever in Chinese medicine may be just what the ... key pain-relieving ingredient is a compound known as dehydrocorybulbine (DHCB) ... , a member of the poppy family, according to researchers ... Current Biology on January 2. "Our study reports ...
Cached Biology News:Genetically identical bacteria can behave in radically different ways 2Genetically identical bacteria can behave in radically different ways 3Odor receptors discovered in lungs 2Odor receptors discovered in lungs 3Odor receptors discovered in lungs 4Plant used in Chinese medicine fights chronic pain 2
Handles samples from from 75l to 150l...
Mouse monoclonal [N7519] to NR0B2 ( Abpromise for all tested applications). Antigen: E.coli expressed recombinant full length protein (Human) NR0B2 Entrez Gene ID: 8431 Swiss Protein ID: ...
Rabbit polyclonal to BCA1 ( Abpromise for all tested applications). Antigen: Generated using E.coli expressed mouse BCA1. Entrez GeneID: 10563 SWISS Protein ID: O43927...
PKC Sampler Kit 10 mu g each...
Biology Products: